During a live event, Ruta Rao, MD, and participants discussed how toxicity history, rather than head-to-head trial data, drives the choice among 3 antibody-drug conjugates once the first one fails or becomes intolerable.

The B7-H3–targeted antibody-drug conjugate tambotatug pelitecan significantly reduced the risk of death in patients with small cell lung cancer.

The application for bezuclastinib in advanced systemic mastocytosisis is supported by data from the APEX trial.

KEYNOTE-D46 shows sacituzumab govitecan plus pembrolizumab misses PFS/OS targets in PD-L1–high metastatic NSCLC, despite higher responses and toxicity.

New RASolute trials test daraxonrasib for metastatic and resected pancreatic cancer, comparing combos and follow-up use to improve outcomes.

The phase 3 DESTINY-Lung04 trial showed first-line trastuzumab deruxtecan extended PFS in patients with HER2-mutant NSCLC.

Updated PRESERVE-003 data showed gotistobart nearly doubled median OS vs docetaxel in previously treated squamous NSCLC.

The approval of lutetium Lu 177 dotatate injection for GEP-NETs is based on results from the ERASMUS study.